Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BNY).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: FTSE (0.1%), DAX +0.2%, CAC +0.1%, IBEX +0.1%, MIB +0.1%

Apr 27 ,2026

  • Synopsis

    • European equity markets set to open mostly flat to higher after last week's losses when the STOXX Europe 600 snapped a five-week winning streak, closing over (2.5%) lower. Asian equities mostly seeing gains Monday. Pickup in risk sentiment attributed to report Iran offered US counterproposal to break deadlock. Another tech-led rally with Japan, South Korean and Taiwan benchmarks outperforming. Crude off earlier highs amid latest diplomatic developments. Gold and silver coming off lows.

    • This week sees ECB, Fed and BOE interest rate decisions, Q1 preliminary GDPs, Apr preliminary CPIs from across the region as well as earnings/updates from the likes of Airbus (AIR.FP), Assa Abloy (ASSA.B.SS), AstraZeneca (AZN.LN), Banco Santander (SAN.SM), Barclays (BARC.LN), BASF (BAS.GR), bp (BP.LN), Iberdrola (IBE.SM), Novartis (NOVN.SW), Prudential (PRU.LN), Stellantis (STLAM.IM), TotalEnergies (TTE.FP), UBS Group (UBSG.SW) and Unilever (ULVR.LN).

    • European macro data releases out today include Germany May consumer confidence - GfK, UK Apr distributive trades - CBI

    • In central banks, ECB's Schnabel panallist at 18:30CET at joint Karlspreis and Helmut Kohl Foundation event "Blossoming Landscapes 2.0 - A New Agenda for Europe". Elsewhere, meeting of EU Agriculture and Fisheries Council takes place whilst EU's Kallas co-chairs the 25th EU-ASEAN ministerial meeting (through Tue) and EU's Hoekstra participates in the Transitioning Away from Fossil Fuels conf (through Wed). In the UK, parliamentary committee topics include northern powerhouse rail at 15:30BST and revisiting the nuclear roadmap at 16:00.

    • On the corporate front today, in M&A news, Apollo funds to acquire Forvia's Interiors group based on EV of €1.82B; Intertek Group rejects previously disclosed acquisition offer from EQT; E.ON looking at buying Ovo Energy, according to Sky News; Whitbread likely to sell, lease back 20% of its freehold Premier Inn hotels, reports Sunday Times. In earnings/updates, Nordex reports broadly better than expected results for Q1, confirms FY26 guidance. In key broker rating changes, stocks that have been upgraded include Commerzbank and Orsted while Sainsbury, ABB and Wizz Air among those that have been downgraded.

  • Politics/Macro/World News

    • Iran gave US new proposal to reopen Strait of Hormuz and end the war, with nuclear negotiations postponed for a later stage -- Axios

    • Rachel Reeves set for new growth push after May elections (FT)

    • Major City reforms to be set out in King's Speech (FT)

    • BoE expected to keep interest rates on hold on Thursday; MPC seen voting 8-1 for no change -- Reuters poll

    • Iran war leads to halving of predicted house price growth in UK (Time s)

    • Slovakia Downgraded To 'A' On Elevated Fiscal Deficits And Rising Debt Burden; Outlook Stable -- S&P

    • Belgium Long-Term Sovereign Ratings Lowered To 'AA-' On Budgetary Imbalances; Outlook Stable -- S&P

    • King's visit to 'revitalise' relationship with US, says UK ambassador -- BBC

  • Top company news

    • Earnings/updates

      • NDX1.GR (Nordex) -- reports Q1 net income €53.6M vs FactSet €42.9M [3 est, €33-48.6M]; FY26 guidance confirmed

      • EXENS.FP (Exosens) -- reports Q1 revenue +19.7% y/y to €122.6M vs FactSet €119.6M [1 est]; fully on track to deliver on 2026 guidance

      • Also reporting today

        • Earnings:

          • DACHs: Deutsche Börse (DB1.GR), Südzucker (SZU.GR), Addex Therapeutics (ADXN.SW)

          • Nordics: Alleima (ALLEI.SS), VBG Group (VBG.B.SS), Fenix Outdoor International (FOI.B.SS), Devyser Diagnostics (DVYSR.SS), Aspo (ASPO.FH), Framery Group (FRAMERY.FH)

          • Southern Europe: Galp Energia (GALP.PL), Linea Directa Aseguradora (LDA.SM), Iberpapel Gestion (IBG.SM), Sogefi (SGF.IM)

          • UK: Bango (BGO.LN), Power Probe (PWR.LN)

        • Trading Update:

          • France: Nacon (NACON.FP)

    • M&A

      • FRVIA.FP (Forvia) -- Apollo funds to acquire Forvia's Interiors group based on EV of €1.82B ($2.13B) (

      • ITRK.LN (Intertek Group) -- rejects previously disclosed acquisition offer from EQT

      • EOAN.GR (E.ON) -- looking at buying Ovo Energy; terms unreported - Sky News

      • WTB.LN (Whitbread) -- likely to sell, lease back 20% of its freehold Premier Inn hotels - Sunday Times

      • GET.FP (Getlink) -- holder Mundys exercises right to acquire up to 25.0% of share capital and 29.9% of voting rights

    • Healthcare

      • NOVN.SW (Novartis) -- Rhapsido receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

      • PFE (Pfizer) -- case against Cipla dismissed; one defendant remains in tafamidis IP suit

      • BBIO (BridgeBio Pharma) -- trading higher following incremental settlement in tafamidis (PFE) IP case

      • ANAB (AnaptysBio) -- Anaptys announces that Delaware Chancery Court dismissed Tesaro's anticipatory breach claim

      • BANB.SW (Bachem Holding) -- AG announces closing of RCF of CHF 500M

      • CANTA.SS (Cantargia) -- announces early results from the ongoing Phase 1b/2a clinical trial evaluating nadunolimab in MDS and AML

      • CRNA.NO (Circio Holding) -- announces that the ongoing feasibility study with a major global pharmaceutical corporation is progressing to in vivo testing

      • CRNA.NO (Circio Holding) -- cancels previously planned subsequent offering of shares

      • OSE.FP (OSE Immunotherapeutics) -- announces FDA grants Orphan Drug Designation to pegrizeprument (VEL‑101) for the prophylaxis of heart allograft rejection in patients receiving a heart transplant

    • Other

      • ERF.FP (Eurofins Scientific) -- Eurofins launches new buyback program for up to 4.5% of its share capital

      • CO.FP (Casino Guichard-Perrachon) -- announces extension of consent from Quatrim creditors

      • SFOR.LN (S4 Capital) -- releases 2025 Annual Report (includes sustainability report on page 27)

      • BP shareholders reject effort to reduce climate reporting while overall ESG-shareholder proposals fall (24-Apr)

      • Estimated weekend box office revenues in US, Canada $150.8M, +2.8% y/y - Box Office Mojo

      • Uber legal risks widen after second verdict for assault claims in litigation themes (24-Apr)

  • Key rating changes

    • Upgrades

      • CBK.GR (Commerzbank) -- to buy from neutral at BofA

      • ORSTED.DC (Ørsted) -- to buy from neutral at Goldman Sachs

      • DIM.FP (Sartorius Stedim Biotech) -- to buy from hold at Intron Health

      • S32.LN (South32) -- to outperform from neutral at BNP Paribas Exane

      • SRT3.GR (Sartorius) -- to buy from hold at Berenberg

      • KGF.LN (Kingfisher) -- to equal weight from underweight at Barclays

      • GRNG.SS (Gränges) -- to buy from hold at Kepler Cheuvreux

      • LIFCO.B.SS (Lifco) -- to buy from hold at SEB

      • HUM.SS (Humana AB) -- to buy from hold at SEB

    • Downgrades

      • WIZZ.LN (Wizz Air Holdings) -- to reduce from hold at Kepler Cheuvreux

      • CAST.SS (Castellum AB) -- to hold from buy at Pareto

      • SBRY.LN (J Sainsbury) -- to sell from buy at Goldman Sachs

      • TOM.NO (Tomra Systems) -- to hold from buy at Handelsbanken

      • MYCR.SS (Mycronic) -- to hold from buy at ABG Sundal Collier

      • NEXI.IM (Nexi SpA) -- to underperform from neutral at BofA

      • ABBN.SW (ABB Limited) -- to hold from buy at Kepler Cheuvreux

  • Data

    • Nikkei +1.46% to 60590.47

    • Hang Seng (0.32%) to 25893.97

    • Shanghai Composite +0.08% to 4083.35

    • S&P futures (3.3) vs prior close of 7194.8

    • €-$ +0.0023 or +0.20% to 1.1724

    • $-¥ (0.19) or (0.12%) to 159.40

    • €-¥ +0.14 or +0.07% to 186.86

    • WTI Crude (Jun 26): +$1.56 or +1.65% to $95.96

    • Gold (Jun 26): ($13.80) or (0.29%) to $4727.10

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

    • BNY.com Terms of Use Privacy Cookie Notice Manage Cookies Disclaimer CUSIP Disclaimer

    • ©  2025 The Bank of New York Corporation. Depositary Receipt business and services are conducted through The Bank of New York.